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Repositioning tolcapone as a potent inhibitor
of transthyretin amyloidogenesis and associated
cellular toxicity
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Transthyretin (TTR) is a plasma homotetrameric protein implicated in fatal systemic
amyloidoses. TTR tetramer dissociation precedes pathological TTR aggregation. Native state
stabilizers are promising drugs to treat TTR amyloidoses. Here we repurpose tolcapone,
an FDA-approved molecule for Parkinson’s disease, as a potent TTR aggregation inhibitor.
Tolcapone binds speciﬁcally to TTR in human plasma, stabilizes the native tetramer in vivo in
mice and humans and inhibits TTR cytotoxicity. Crystal structures of tolcapone bound to
wild-type TTR and to the V122I cardiomyopathy-associated variant show that it docks better
into the TTR T4 pocket than tafamidis, so far the only drug on the market to treat TTR
amyloidoses. These data indicate that tolcapone, already in clinical trials for familial amyloid
polyneuropathy, is a strong candidate for therapeutic intervention in these diseases, including
those affecting the central nervous system, for which no small-molecule therapy exists.
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T
he misassembly of soluble proteins into toxic aggregates,
including amyloid ﬁbrils, underlies a variety of human
diseases1. Transthyretin (TTR) is a homotetrameric
protein produced mainly in the liver and in the brain’s choroid
plexus, and circulates in plasma and cerebrospinal ﬂuid2,3. TTR
aggregation is associated with senile systemic amyloidosis (SSA)3,
familial amyloid cardiomyopathy (FAC)4 and familial amyloid
polyneuropathy (FAP)5. SSA and FAC are caused by aggregation
and deposition of wild-type and mutant TTR, respectively,
preferentialy in the heart. FAP is characterized by mutant TTR
deposition in peripheral and autonomic nerves and the heart,
but also in other sites such as the lung, carpal tunnel and gut.
More than 100 different TTR variants have been reported6. For
some rare TTR mutations aggregation develops in the
central nervous system, resulting in amyloid deposits in the
leptomeninges, in the brain parenchyma, and in the eyes7–9.
Plasma TTR binds and transports holo retinol binding protein
and thyroxine (T4), whereas in the cerebrospinal ﬂuid it
transports T4 only10. TTR is composed of four identical 127
amino-acid residue b-sheet-rich subunits, termed A, B, C and
D11. The TTR tetramer is formed by association of the AB and
CD dimers. The weaker dimer–dimer interface deﬁnes two,
largely unoccupied (o1% T4 bound), funnel-shaped T4-binding
sites12. Tetramer dissociation is the rate-limiting step for
TTR aggregation13,14. Accordingly, autosomal dominant
mutations often destabilize TTR tetramer, thus increasing
amyloidogenesis15,16.
For many years, liver or combined liver and heart transplanta-
tion were the only palliative treatments for the TTR amyloi-
doses17. More recently, it has been shown that small molecules
able to bind to the TTR T4-binding sites increase the energy
barrier of tetramer dissociation, acting as kinetic stabilizers, thus
stalling TTR aggregation18–28. A pharmacologic strategy, based
on stabilization of the TTR native tetramer by the benzoxazole
tafamidis has been approved in Europe and Japan for the
treatment of early-stage FAP29,30. However, tafamidis might not
be potent enough to treat advanced TTR amyloidoses31. The lack
of an Food and Drug Administration (FDA)-approved candidate
for the treatment of TTR amyloidoses reﬂects the difﬁculty of
moving from the discovery of in vitro hits to the development of
clinically effective and safe drugs. Drug repositioning offers a
potentially valuable and productive approach to identify
candidates for new pharmacologic applications. The process
involves the identiﬁcation of existing compounds licensed for a
different therapeutic indication32. Those candidates have already
established safety proﬁles, reducing the time and cost required to
bring them to trial and into the clinic for their new indication.
Diﬂunisal, an FDA-approved nonsteroidal anti-inﬂammatory
agent, acts as a TTR kinetic stabilizer33,34. Although its in vitro
afﬁnity for TTR T4-binding sites is signiﬁcantly lower than that of
tafamidis, a randomized clinical trial has shown that the diﬂunisal
treatment of patients with FAP for 2 years reduced the rate of
progression of neurological impairment35, demonstrating the
validity of drug repurposing for TTR amyloidoses.
Here we identify tolcapone as a potential inhibitor of TTR
amyloidogenesis. Tolcapone is an orally active cathecol-O-
methyltransferase (COMT) inhibitor authorized in the United
States and Europe as an adjunct to levodopa and carbidopa for
the treatment of Parkinson’s disease. We show that tolcapone
binds speciﬁcally to TTR, stabilizes both wild-type (WT-TTR)
and mutant TTR variants, reduces their aggregation and prevents
TTR-induced cardiotoxicity more effectively than tafamidis.
X-ray crystallography and calorimetric assays reveal the mole-
cular determinants that account for the activity of tolcapone in
both WT-TTR and the V122I cardiomyopathy-associated variant.
The anti-aggregational properties of this repositioned drug make
it an ideal candidate for the therapeutic treatment of the TTR
amyloidoses.
Results
Tolcapone inhibits TTR aggregation. The Symyx Comprehen-
sive Medicinal Chemistry database includes compounds under
clinical development, phase II-III and molecules already approved
for human use. A total of 30 compounds were selected for further
experimental characterization (Supplementary Table 1). We ﬁrst
tested the anti-TTR aggregational activity of these molecules in
the 0–40 mM range with the highly amyloidogenic Y78F-TTR
variant at pH 4.2 (ref 36). This acidic pH induces TTR aggregation
increasing thus sample turbidity and light scattering15.
Supplementary Table 1 shows the obtained EC50 values for
TTR aggregation inhibition. The most active compound exhibits
an EC50 of 3.92±0.30 mM and corresponds to the commercial
drug tolcapone (Tasmar, CAS 134308-13-17; Fig. 1a). Under the
same conditions, tafamidis displays an EC50 of 5.36±0.57 mM.
We validated these results by testing the capacity of tolcapone to
prevent aggregation of WT-TTR and the FAC-associated V122I-
TTR variant37 at pH 4.4 (refs 38,39). Tolcapone was highly
effective at inhibiting both WT-TTR and V122I-TTR aggregation
with EC50 values of 1.50±0.12 and 4.72±0.45 mM, respectively,
as measured by light scattering (Fig. 1b,c). Under the same
conditions, tafamidis displayed EC50 values of 4.78±0.47 and
8.35±0.80 mM for WT-TTR and V122I-TTR, respectively
(Fig. 1b,c). At any TTR/drug ratio tested, tolcapone exhibited
a stronger aggregation inhibitory activity than tafamidis.
We conﬁrmed tolcapone’s anti-aggregational activity using
sedimentation assays (Supplementary Fig. 1a). The A25T-TTR
variant is among the most destabilized and fastest dissociating
TTR tetramers8; however, it only causes an amyloid pathology in
the brain. Because of its instability, the protein is mostly degraded
in the liver and not secreted into the bloodstream. The high
concentration of T4 in the choroid plexus acts as a kinetic
stabilizer allowing A25T-TTR folding and secretion16, but once
secreted the tetramers dissociate, resulting in amyloid deposition
in the leptomeninges. As tolcapone is able to cross the blood–
brain barrier40, we tested whether it could reduce the aggregation
of this variant in vitro. A25T-TTR (3.6mM) was incubated in the
presence or absence of tolcapone (0–20 mM) at pH 5.0 and 37 C
for 22 h, where this variant exhibits maximum amyloidogenicity8.
A25T-TTR requires only 1 h to become fully aggregated due to its
high kinetic unstability8. Four molar equivalents of tolcapone
(15 mM) sufﬁced to reduce between 40% (Fig. 1d) and 50%
(Supplementary Fig. 1b) of A25T-TTR aggregation, resembling the
anti-aggregational activity exerted by T4 at the same pH (ref. 8).
Tolcapone kinetically stabilizes TTR. We addressed whether the
anti-aggregational effect of tolcapone was mediated by tetramer
stabilization. In urea, TTR tetramer dissociation precedes
monomer unfolding, a process easily tracked by monitoring
changes in intrinsic Trp ﬂuorescence41. WT-TTR was incubated
in the presence or absence of tolcapone (10molar equivalents
with respect to TTR; that is, 5molar equivalents of tolcapone per
TTR-binding site) and increasing concentrations of urea
(0–9M) for 72 h. Tolcapone does not interfere with TTR Trp
ﬂuorescence (Supplementary Fig. 2), therefore, Trp ﬂuorescence
was measured to calculate the percentage of folded protein at any
given urea concentration15. Tolcapone exerted a strong stabilizing
effect, allowing more than 80% of TTR to remain in the native
state upon incubation in 8M urea (Fig. 1e).
At high denaturant concentrations, the rate of TTR tetramer
dissociation is linked irreversibly to monomer unfolding.
WT-TTR (1.8mM) was incubated in the absence and presence
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of tolcapone (0.25–10molar equivalents with respect to TTR) in
6.5M urea at room temperature (RT). Intrinsic ﬂuorescence was
recorded after 72 h. In the presence of 2 and 4molar equivalents
of tolcapone, only, 33.8 and 8% of WT-tetramer, respectively,
were unfolded, indicating a dose-dependent kinetic stabilization
of TTR tetramer (Fig. 1f).
Tolcapone binds with high afﬁnity to TTR. The strong
stabilizing and anti-aggregational activity of tolcapone suggest
that it binds tightly to the TTR T4-binding sites. The ability of
tolcapone and tafamidis to compete with T4 for TTR binding
was assessed by a gel ﬁltration assay42. Competition binding
experiments using radiolabelled T4 and WT-TTR were performed
in the presence of different concentrations of test compounds and
the T4 fraction bound to TTR was separated from the unbound
fraction by gel ﬁltration. The EC50 values for tolcapone and
tafamidis were 41.4 and 183.5 nM, respectively; thus tolcapone
displaces radiolabelled T4 from TTR 4 times more efﬁciently than
tafamidis.
We used isothermal titration calorimetry (ITC) to conﬁrm the
binding of tolcapone to WT-TTR (Fig. 2a). We also evaluated
tolcapone binding to the FAC-associated V122I-TTR variant
(Fig. 2b). Data analysis was performed considering two models:
Model 1: Two identical and independent binding sites; Model 2:
Two identical and cooperative binding sites43,44. The ﬁt using
model 2 was better for WT-TTR, whereas model 1 was better for
V122I, according to parametric (F test) and non-parametric tests
(Akaike’s and Bayesian information criteria).
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Figure 1 | Tolcapone and tafamidis effects over WT, V122I-TTR and A25T-TTR aggregation and stability. (a) Chemical structures of the commercially
available drugs tolcapone (Tasmar, CAS 134308-13-17) and tafamidis. Anti-amyloidogenic effect of tolcapone and tafamidis on (b) WT-TTR and
(c) V122I-TTR and (d) anti-amyloidogenic effect of tolcapone on A25T-TTR. TTR solutions were incubated with several concentrations of test molecules
and aggregation was induced by acidiﬁcation. Turbidity at 340nm was used to monitor TTR aggregation and ﬁbril formation. At the end of the assays, the
percentage of TTR aggregation for each experimental condition was calculated with respect to the TTR turbidity values obtained in the absence of
compounds (vehicle only). (e) WT-TTR was incubated in the presence or absence of 10molar equivalents of tolcapone. Urea was added to promote protein
unfolding at the indicated ﬁnal concentrations. (f) WT-TTR was incubated with several concentrations of tolcapone (from 0.25 to 10molar equivalents with
respect to WT-TTR) and denaturation promoted by addition of urea at a ﬁnal concentration of 6.5M. In both assays e and f, after 72 h incubation at RT,
Trp ﬂuorescence intensity (355/335 nm) was measured as a sensor of tetramer integrity. TTR stabilization effect induced by tolcapone binding was
calculated with respect to the tryptophan ﬂuorescence emission of the protein in the absence of the compound (vehicle only). In all panels, error bars
indicate the standard error of the mean (s.e.m.; n¼ 3).
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According to model 2, tolcapone binds to WT-TTR with
Kd1¼ 21 nM and Kd2¼ 58 nM. In the case of tafamidis binding
to WT-TTR, we obtained Kd1 and Kd2 values of 5.7 and 260 nM,
respectively (Supplementary Fig. 3). These data are consistent
with previously published experiments where Kd1 and Kd2
for tafamidis binding to WT-TTR were found to be
3.0–4.4 nM and 278–280 nM, respectively29,45. For tolcapone,
the binding of the ﬁrst ligand displays favourable binding
enthalpy (Dh1¼  8.7 kcalmol 1) and binding entropy
(TDs1¼ 1.8 kcalmol 1; Fig. 2c). This ﬁrst binding event is thus
enthalpically driven, suggesting speciﬁc interactions between
protein and ligand. The binding of tolcapone to the second site is
almost entirely enthalpically driven (Dh2¼  9.7 kcalmol 1 and
TDs2¼ 0.2 kcalmol 1), which again suggests the formation of
speciﬁc interactions.
According to model 1, tolcapone shows identical binding
afﬁnity for both V122I-TTR T4-binding sites, with a Kd¼ 56 nM.
The binding of tolcapone to V122I-TTR is entirely enthalpically
driven with Dh¼  11.5 kcalmol 1 for each independent
binding site and an unfavourable binding entropy TDs¼ 1.6
kcalmol 1. From our ITC studies we estimate the Kd2 for
binding of tafamidis to V122I-TTR to be 1.1 mM (Supplementary
Fig. 3). These data are in agreement with previously published
subunit exchange assays that estimate that the Kd2 of tafamidis
for binding to V122I-TTR would be in the mM range45.
Tolcapone stabilizes the TTR dimer–dimer interface. We
obtained a co-crystal structure of tolcapone and WT-TTR at
1.15 Å (Fig. 3a,b, Supplementary Table 2 and Supplementary
Fig. 4). This high-resolution crystal allows the unambiguous
placement of tolcapone in the butterﬂy-shaped electron density
map of the TTR dimer–dimer interface. The twofold symmetry
axis along the hormone-binding pocket creates two binding
modes of tolcapone related by a 180 rotation. The 4-methyl-
phenyl ring of tolcapone sits deep within the inner cavity of the
T4-binding site, establishing hydrophobic interactions with
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Figure 2 | Interaction of TTR with tolcapone assessed by ITC. Top panels: Thermogram (thermal power versus time) after baseline correction; bottom
panel: binding isotherm (normalized heat versus molar ratio of reactants). (a) WTand (b) V122I-TTR. The solid line corresponds to the best ﬁt for each of
the proteins. For WT-TTR, the data were ﬁt by a general binding model for a protein with two ligand-binding sites. The non-linear regression analysis
provided the estimations for the overall binding parameters: b1¼ 9.3 107M 1, DH1¼  8.7 kcalmol 1, b2¼ 7.9 1014M 2, DH2¼  18.4 kcalmol 1.
Nonlinear regression analysis indicated that V122I-TTR has two identical and independent binding sites for tolcapone and provided the estimations for the
common binding parameters: b1¼ 1.8 107M 1, DH1¼  11.5 kcalmol 1. (c) Site-speciﬁc binding parameters for the ﬁrst and second ligand bound to
WT-TTR can be calculated from the overall binding parameters: Kd1¼ 21 nM, Dh1¼  8.7 kcalmol 1, Kd2¼ 58 nM, and Dh2¼  9.7 kcalmol 1. Common
binding parameters for V122I-TTR sites were calculated to be Kd1¼ 56nM, Dh1¼  11.5 kcalmol 1. Relative error in the association constants is 15%, error
in binding enthalpies is 0.3 kcalmol 1.
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residues composing the two symmetrical T4-Halogen-Binding
Pockets HBP2–20 and HBP3–30 (Ala108, Leu110, Ser117 and
Thr119). In addition, a speciﬁc hydrogen bond interaction is
formed between the central carbonyl group of tolcapone and the
hydroxyl side chain of Thr119 (at 2.55Å). The side-chains of
Thr119 and Ser117 display two or three different conformations,
respectively, probably caused by the interaction with the two
symmetrical binding modes of tolcapone. On the outer binding
region, the 3,4-dihydroxy-5-nitrophenyl ring of tolcapone is
placed in the hydrophobic environment created by residues from
the HBP2 and -20 and HBP1 and -10 pockets (Lys15, Leu17,
Thr106 and Ala108). Remarkably, in this outer binding pocket
the e-amino group of Lys15 is sandwiched between the two
hydroxyl groups of the phenyl ring of tolcapone (at 2.97 and
3.22Å, respectively) and the carboxylate group of Glu54 (2.87Å;
Fig. 3b). These electrostatic interactions by Lys15 close the cavity
around tolcapone, restricting the entrance of solvent into the HBP
pockets (Supplementary Fig. 4) in such a way that the tolcapone
salt bridge with Lys15 and the polar interactions with Thr119 are
both partially shielded. The higher solvation interface between
dimers in the TTR/tolcapone crystal structure with respect to the
TTR/tafamidis structure (Supplementary Fig. 4) suggests a lower
water rearrangement, contributing thus to tolcapone’s lower
desolvation entropy for binding.
We also obtained a co-crystal structure of tolcapone and
V122I-TTR at 1.9 Å resolution (Fig. 3d,e and Supplementary
Table 2). This is of particular relevance as the V122I mutation
impacts directly the weaker dimer–dimer interface, resulting in an
increased rate of tetramer dissociation37. As for the WT-TTR
co-crystal, the twofold symmetry axis along the hormone-binding
pocket creates two binding modes of tolcapone related by a 180
rotation. The conformation of tolcapone in the T4-binding site
and the contacts it establishes with the mutant V122I protein are
virtually identical to those found when it is bound to WT-TTR,
explaining why tolcapone is also a high-afﬁnity binder and a
more effective aggregation inhibitor of the kinetically unstable,
FAC-associated, V122I-TTR than tafamidis (Fig. 3f).
Tolcapone selectively binds to TTR in human plasma.
To become a drug for TTR-related diseases, tolcapone should
selectively bind to TTR among the more than 4,000 human
plasma proteins. To test this notion, tolcapone (10.8mM ﬁnal
concentration) was added to human plasma and the samples were
incubated for 24 h at 37 C. The TTR concentration in plasma is
in the 2.8–5.4 mM range; thus, sufﬁcient ligand was present in the
assay to saturate the two TTR-binding sites, assuming that the
submicromolar ITC-derived Kds are also valid in this milieu.
Plasma TTR was then immunoprecipitated and the
stoichiometry of tolcapone relative to TTR in the precipitated
fraction quantiﬁed by high-performance liquid chromatography.
An assay using tafamidis was performed under the same
conditions. The maximal binding stoichiometry possible is 2,
because there are 2 T4-binding sites per TTR tetramer. The
TTR-binding stoichiometry obtained for tolcapone in plasma is
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Figure 3 | Crystal structures of WT-TTR/ligand and V122I-TTR/ligand complexes. (a) Global view of WT-TTR bound to tolcapone (ribbon
representation). The electron density map of the two T4-binding sites of tolcapone are depicted. Broken line indicates the twofold symmetry axis
of the dimer–dimer interface. Detailed and close up view of one of the WT-TTR T4-binding sites are shown in b for tolcapone (PDB: 4D7B) and c for
tafamidis (PDB: 3TCT). (d) Global view of V122I-TTR bound to tolcapone (ribbon representation). The electron density map of the two T4-binding sites of
tolcapone are depicted. Broken line indicates the twofold symmetry axis of the dimer–dimer interface. Detailed and close up view of one of the V122I-TTR
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0.87±0.09, whereas that of tafamidis is 1.12±0.09 (ligand/TTR),
a value consistent with that previously reported29. These ratios
represent a lower limit for the compound/TTR stoichiometry due
to possible loss of bound compounds during sample processing.
In any case, the data support tolcapone, as tafamidis, being highly
selective for TTR in human plasma.
We next tested the capacity of tolcapone and tafamidis to
compete with T4 for TTR binding in human plasma from a
normal (WT-TTR) and from an FAP patient carrying the
V30M-TTR mutation. Plasma in the presence or absence of
tolcapone and tafamidis was incubated with [125I]-labelled T4,
followed by separation of T4-binding proteins using native gel
electrophoresis and autoradiography (Fig. 4a)42. In both samples,
in the absence of compounds, three main plasma proteins bind
T4: T4-binding globulin (TBG), albumin (ALB) and TTR. In the
presence of tolcapone and tafamidis, the radioactive T4-TTR band
is no longer visible, indicating that these molecules can selectively
compete with T4 for TTR binding in plasma.
Tolcapone stabilizes WT-TTR and V30M-TTR in human plasma.
The ability of tolcapone to prevent TTR tetramer dissociation in
the plasma of normal and FAP V30M patients was monitored by
isoelectric focusing (IEF) electrophoresis under semi-denaturing
conditions (4M urea). Tafamidis was also used as control. Plasma
samples were incubated with 1.4mM solution of test compounds
overnight at 4 C followed by 1 h incubation at RT. Samples
were processed as detailed in the experimental section42.
A representative gel is shown in Fig. 4b. The presence of TTR
monomer (M), oxidized monomer (Ox M) and several bands of
lower pI corresponding to tetramers can be discriminated. The
extent of tetramer stabilization was calculated as the ratio of
tetramer over total TTR in the presence of compounds, relative to
the same value in their absence. Tafamidis and tolcapone
stabilized WT and V30M-TTR tetramers in plasma, with
tolcapone displaying a higher stabilizing activity (Fig. 4b).
Stabilization of plasma TTR under physiological conditions
was conﬁrmed using an immunoturbidity assay29 (Fig. 4c).
A pool of human plasma from healthy volunteers was incubated
with different concentrations of tolcapone before denaturation
with 4.8M urea during 48 h. After urea treatment, samples
were crosslinked with glutaraldehyde and the concentration of
TTR determined by immunoturbidity. Treatment with urea
and glutaraldehyde decreases immunoturbidity signal due to
the extensive modiﬁcation of denatured TTR monomers by
glutaraldehyde, hampering antibody recognition33. As TTR
denaturation is preceded by tetramer dissociation, the signal
roughly correlates with tetramer stability. Preincubation with
tolcapone stabilized TTR in a dose-responsive manner, conferring
resistance to urea denaturation and preventing the loss of signal
after 48 h of urea treatment (Fig. 4c).
Tolcapone prevents TTR-induced cytotoxicity in cell culture.
To test the potential therapeutic activity of tolcapone for the
cardiac forms of TTR amyloidoses, we used an established cell
model system based on the use of AC16 cells46, a human cardiac
cell line derived from adult cardiomyocytes of the ventricle, theWT plasma V30M plasma
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Figure 4 | Tolcapone selectively binds and stabilizes WTand V30M-TTR
in human plasma. (a) Human plasma of control or V30M-TTR carriers
were incubated with [125I]T4 in the presence or absence of tolcapone or
tafamidis (ﬁnal concentration¼ 1mM). After 1 h at RT, the plasma proteins
were separated by native gel electrophoresis. The gel was subjected to
phosphor imaging and the radioactive bands were quantiﬁed. The band of
TTR bound to radioactive T4 is not present in the plasma samples incubated
with the small molecules, indicating an almost complete and selective
displacement of T4 from the TTR-binding pocket by the compounds.
Uncropped images of the ﬁlms are shown in Supplementary Fig. 6.
(b) Human plasma was incubated with 1.5mM of tolcapone or tafamidis
and tetramer stability assessed by IEF under semi-denaturing conditions62.
The increase of the ratio between tetramers and other species in the gels is
an indicator of TTR stabilization in drug-treated samples. Quantiﬁcation of
bands shows higher proportion of tetramers in the plasma samples treated
with tafamidis and particularly in those treated with tolcapone. ‘T’, ‘Ox M’
and ‘M’ indicate Tetramer, Oxidized Monomers and Monomers,
respectively. Error bars indicate s.e.m. (n¼ 3). Uncropped images of the
gels are shown in Supplementary Fig. 7. (c) Human plasma samples were
incubated with several concentrations of tolcapone for 15min at RT. After
incubation, an aliquot was separated for total TTR determination (control).
Urea buffer was added and samples were incubated at RT for 0 or 48 h.
After the indicated incubation times, the samples were crosslinked with
glutaraldehyde as detailed in the experimental section, and the tetrameric
TTR concentration determined by immunoturbidity. Addition of tolcapone
to the plasma results in dose-response stabilization of tetrameric TTR. Error
bars indicate s.e.m. (n¼ 3).
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site of TTR deposition in FAC and SSA47,48. AC16 cells were
treated with 8 mM of cytotoxic WT-TTR and V122I-TTR
incubated in the presence or absence of tafamidis or tolcapone
(16 mM; i.e., two molar equivalents with respect to TTR). Cell
treatment with WT-TTR and V122I-TTR alone caused a
signiﬁcant reduction in cell viability measured by resazurin
reduction assay (B60%). Both tafamidis and tolcapone rescued
this toxic effect, with tolcapone exhibiting a higher protective
activity (Fig. 5a).
We also analysed whether the TTR anti-aggregational activity
of tolcapone results in a reduction of the toxicity associated with
the formation of Y78F-TTR oligomers in a FAP cell culture
model49. Y78F-TTR was incubated in the absence or presence of
the selected compounds at 37 C for 6 days to generate cytotoxic
oligomers. Rat Schwannoma cells (RN22) were exposed to these
aggregates (2 mM) for 24 h and cell lysates were used to determine
Caspase-3 activation levels. The addition of TTR aggregates in the
absence of compounds increased the intracellular levels of
Caspase-3 compared with control cells (Fig. 5b). Incubation
with tolcapone and tafamidis promoted 27.8%±6.1 and
11.6%±4.0 reduction in Caspase-3 activation, respectively
(Fig. 5b).
To determine whether tolcapone can inhibit extracellular TTR
ﬁbrillogenesis under physiological conditions, we used RN22 cells
stably transfected with the highly pathogenic FAP-associated
L55P-TTR variant50 under the control of the metallothionein
promoter51. Upon induction with ZnSO4, cells secreted L55P-
TTR to the extracellular milieu. RN22 cells were incubated with
1 mM of tolcapone or tafamidis in the medium for 48 h, the
expression of the recombinant protein was induced by addition of
100 mM ZnSO4 and the incubation continued for 24 h. The extent
of extracellular L55P-TTR aggregation was monitored by a ﬁlter
trap assay followed by TTR immunodetection. Both compounds
exhibited strong effect, reducing B90% L55P-TTR aggregation
compared with untreated cells (Fig. 5c).
Tolcapone binds to and stabilizes TTR in transgenic mice. We
addressed the effects of tolcapone in transgenic mice expressing
the FAP-associated human V30M-TTR variant52. A dose of
tolcapone ranging from 30 to 300mg kg 1 was administered by
gavage, followed by an identical dose after 8 h; alternatively the
rodents were treated with three or four consecutive doses of
100mg kg 1 spaced every 3 h. The animals were killed 1 h after
the last dose. Plasma samples were obtained before dosing (t¼ 0)
and at the end of the experiment. T4 competition assays by native
gel electrophoresis were performed in plasma following the same
protocol as in Fig. 4a. At basal conditions (t¼ 0), around 40% of
the total radioactivity was associated with the TTR band in
samples from all animals. At the end of the treatment, the amount
of T4 remaining bound to TTR decreased in a dose-dependent
manner (Fig. 6a), indicating that tolcapone binds to the TTR
T4-binding sites in vivo.
The ability of tolcapone to stabilize V30M-TTR in the plasma
of animals was analysed under semi-denaturing conditions by
isoelectric focusing as in Fig. 4b. The tetramer/total TTR ratio in
the plasma of tolcapone-treated animals was higher than in those
treated with vehicle alone (Fig. 6b), indicating that the binding of
the compound to TTR results in a signiﬁcant stabilization of the
native V30M-TTR state in vivo.
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Figure 5 | Tolcapone prevents TTR-induced cytotoxicity of TTR variants
and inhibits L55P-TTR aggregation under physiological conditions.
(a) Tolcapone protects human cardiomyocytes from the toxic effect of
V122I-TTR and WT-TTR. AC16 cells were incubated for 24 h with WT or
V122I-TTR in the presence or absence of 2molar equivalents of tolcapone
or tafamidis. Resazurin reduction assay was used to measure cell viability.
Percentage of cell viability was calculated compared with cells treated with
vehicle only. Both compounds rescued the cells from the toxicity induced by
TTR. Error bars indicate s.e.m. (n¼8). (b) Tolcapone lowers cytotoxicity of
Y78F-TTR aggregates. RN22 cells were exposed to aggregates generated in
the absence or presence of tolcapone or tafamidis for 24 h. Caspase-3
activation on cell lysates was used to probe cytotoxicity. Both compounds
lowered caspase-3 activation promoted by the aggregates. Error bars
indicate s.e.m. (n¼4). (c) Tolcapone prevents aggregation of L55P-TTR
under physiological conditions. RN22 cells expressing L55P-TTR under the
control of methallothienin promoter were incubated in the presence or
absence of tolcapone or tafamidis (1mM). Secreted L55P-TTR aggregation
was monitored by a ﬁltration assay followed by a dot blot (representative
blot triplicates are shown on the right panel). Uncropped images of the
blots are shown in Supplementary Fig. 8. Filtration of the medium retains
high molecular mass aggregates that are detected using a rabbit anti-
human TTR antibody. Intensities of the dots were measured, percentage of
aggregation was calculated with respect to cells treated with vehicle, and
plotted as bars (left panel). Error bars indicate s.e.m. (n¼ 3).
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Orally administered tolcapone stabilizes TTR in humans. TTR
stabilization by tolcapone was also conﬁrmed in humans, using
plasma samples from two healthy volunteers treated with a
commercial oral formulation of tolcapone. One volunteer (HV1)
was treated with a dose of 200mg of tolcapone, a usual dose
for Parkinson’s treatment, and the other (HV2) with 400mg
administered as two sequential doses of 200mg, separated by a
30-min interval. Plasma samples were obtained 30min before
(basal) and 2 h after the last administration, which is the time
at which peak plasma concentration occurs (Tmax)53. The
concentration of tolcapone in all plasma samples was measured
using an ultra-performance liquid chromatographic (UPLC)-MS/
MS analytical method (see Methods for details; Table 1). TTR
stabilization in vivo was measured using an immunoturbidimetric
assay as in Fig. 4c. The fraction of initial tetramer concentration
(FOI) was determined in triplicate for each sample (FOI¼TTR
tetramer after 48 h urea treatment/TTR tetramer at time 0 in the
presence of urea).
As shown in Fig. 6c, oral treatment with tolcapone stabilizes
TTR, preventing its denaturation. In the absence of tolcapone
(basal), there was a signiﬁcant loss of tetrameric TTR signal after
urea treatment (compare 0 h urea and 48 h urea bars in basal
samples). The FOI in basal samples of subjects HV1 and HV2
were 0.17±0.00 and 0.18±0.01, respectively. In contrast, after
treatment with tolcapone, the loss of TTR tetramer signal after
48 h of urea treatment is very low, with FOI values of 0.78±0.04
and 0.98±0.02 in HV1 and HV2, respectively, achieving in the
later an almost complete protection against urea-induced TTR
tetramer denaturation. These data are consistent with the fact that
the measured tolcapone levels in HV2, who received two doses of
tolcapone, were higher than those found in HV1 (Table 1).
Altogether these results indicate that oral administration of
tolcapone in humans effectively stabilizes native tetrameric TTR.
According to the Vyndaqel European Public Assessment Report
(EMA/815723/2011), following a single dose of 120mg tafamidis,
the average concentration of tafamidis in plasma at Tmax was
14.4 mM, which resulted in an average percent stabilization of
TTR of 189%. For tolcapone, after a single dose of 200mg,
its concentration in plasma at Tmax was 13.6 mM, resulting in
359% TTR stabilization; these data indicate that at similar Tmax
concentrations, tolcapone TTR stabilization capacity is 1.9-fold
higher than that of tafamidis.
Discussion
According to the National Institutes of Health, the average time
between the discovery of a new drug candidate and its market
approval is 13 years—a process with an associated failure rate
higher than 95%, and an average cost of $1,778 million54.
Repurposing FDA-approved drugs for new indications can offer
an accelerated pathway for new treatments because of faster early
phases of clinical development, shortened drug optimization
timelines and reduced failure rates due to pharmacokinetic and
safety issues. Therefore, one of the National Institutes of Health
missions consists in repurposing known drugs for new
indications.
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Figure 6 | Tolcapone is orally available and stabilizes TTR in humans and
in transgenic mice expressing the amyloidogenic human V30M-TTR
variant. (a) T4 competition was assessed by gel electrophoresis of plasma
samples from the transgenic mice expressing human V30M-TTR, before
and after oral administration of tolcapone (t¼0 and t¼ end, respectively).
Plasma samples were treated with radiolabelled T4 and subjected to native
PAGE. The fraction of radiolabelled T4 bound to the band corresponding to
TTR is represented. Error bars indicate s.e.m. (n¼4). (b) TTR tetramer
stability in the plasma of control and tolcapone-treated transgenic mice was
assessed by IEF under semi-denaturing conditions62. The ratio between the
TTR tetramers and the rest of the TTR species in the IEF gels was calculated
for controls and tolcapone-treated mice. The data are expressed as fold
increase of the ratio TTR tetramer/total TTR with respect to samples from
vehicle-treated animals. ***Po0.001 and **Po0.01 (Student’s t-test). Error
bars indicate s.e.m. (n¼ 3). (c) Tetrameric TTR stabilization in plasma from
humans treated with an oral dose of 200 or 400mg of tolcapone (subjects
HV1 and HV2, respectively). TTR stabilization was quantiﬁed by
immunoturbidity after urea denaturation with subsequent crosslinking with
glutaraldehyde as detailed in the experimental section. Basal, indicates
plasma obtained before tolcapone administration. White bars correspond to
plasma samples crosslinked 0 h after urea addition, black bars correspond
to plasma samples crosslinked after 48 h of urea denaturation. Bars
correspond to average TTR tetramer concentration of three independent
determinations, error bars represent standard deviation (n¼ 3).
Table 1 | Concentration of tolcapone in human plasma
samples from treated individuals.
Subject Tolcapone
dose
Basal sample Dosed sample*
Subject HV1 200mg o0.2 mgml 1 3.7mgml 1 (13.6mM)
Subject HV2 2 200mg o0.2 mgml 1 20.6 mgml 1 (75.6mM)
*Dosed sample corresponds to plasma collected 2 h after drug administration (Tmax).
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Diﬂunisal, the only FDA-approved drug that has already
shown to inhibit FAP progression in clinical trials35 is a
promising molecule to preserve the quality of life in patients
affected by hereditary TTR amyloidosis. However, diﬂunisal can
produce signiﬁcant gastrointestinal and cardiovascular side effects
and thus, it may not be appropriate for chronic administration
to a large subpopulation of patients, such as those with high
blood pressure, or with already compromised gastrointestinal
systems55,56. Therefore, additional alternative, potent and safe
small molecules are still needed to effectively treat the TTR
amyloidoses.
We describe here how the application of a drug repositioning
protocol for the TTR amyloidoses has crystallized in the discovery
of tolcapone, a promising FDA-approved drug for the treatment
of SSA, FAP, FAC and uniquely, TTR leptopmeningeal
amyloidosis.
Tolcapone occupies the T4-binding sites located at the TTR
dimer–dimer interface, being able to dock into these pockets with
notable selectivity in the highly protein-crowded human plasma
environment. The binding of tolcapone to the TTR T4 pockets is
not expected to result in thyroid metabolic defects because the
contribution of TTR to plasma T4 transport is low, relative to that
of TBG and ALB10,57.
Tolcapone binding to the TTR’s T4 pockets prevents
amyloidogenesis by acting on the protein native state, raising
the energy barrier for tetramer dissociation, which is the rate-
limiting step of the TTR amyloid formation cascade15,41. This
mode of action is nowadays the preferred therapeutic approach
for TTR amyloidosis treatment as it appears that soluble
oligomeric species, presumably amyloid ﬁbril precursors, exert
the main cytotoxic effects in tissues, well before there is massive
protein deposition58,59.
In vitro, tolcapone binds with high afﬁnity and strongly
inhibits the aggregation of WT-TTR as well as the kinetically
unstable V122I-TTR variant, involved in cardiac TTR amyloi-
dosis. It also inhibits the aggregation of the leptomeningeal-
associated A25T-TTR variant. Importantly, tolcapone is
signiﬁcantly more potent than tafamidis at preventing TTR
aggregation, independently of the TTR variant, concentration and
assay used for its evaluation.
Tolcapone’s stabilizing effect rescues WT- and V122I-TTR-
induced cardiotoxicity in a well-characterized cell culture model
system for FAC47,48. In the absence of a transgenic mouse model
expressing the human V122I-TTR variant, this cardiac tissue
culture system using adult cardiomyocytes of the ventricle,
the site of TTR deposition, is the most pathophysyologically
relevant system for V122I-TTR cardiac amyloidosis46. Moreover,
tolcapone partially prevents caspase-3 activation induced by
Y78F-TTR oligomers in the RN22 cellular model for FAP49. In
both the FAC and the FAP cellular model systems, the protective
activity of tolcapone against TTR proteotoxicity was higher than
that of tafamidis.
Tolcapone binds to and kinetically stabilizes tetrameric TTR
ex-vivo in human plasma from WT-TTR individuals and from
carriers of V30M-TTR, the most common FAP-associated TTR
variant worldwide60. It also stabilizes human V30M-TTR in vivo
in plasma from transgenic mice, after oral administration
of the drug. Importantly, tolcapone prevents native WT-TTR
dissociation and amyloidogenesis in vivo in human subjects.
The co-crystal structures obtained for WT-TTR and
V122I-TTR with tolcapone indicate that the small-molecule
interacts with both the inner cavity and the periphery of the
T4-binding site. The binding of tolcapone involves more polar
contacts as well as hydrophobic interactions than in the case of
tafamidis. The formation of a speciﬁc hydrogen bond with
Thr119 and Thr1190 and a salt bridge with Lys15 and Lys150 at
the dimer–dimer interface might explain why the binding of
tolcapone to the T4 sites is essentially enthalpically driven. This is
particularly true for binding to V122I-TTR. Indeed, V122 is
located on the periphery of the H b-strand, which forms an
antiparallel b-sheet with another monomer, stabilizing the
AC/BD dimer interface. The V122I mutation impacts directly
on the stability of this interface and tolcapone compensates this
destabilizing effect by bridging the H b-strands of adjacent
monomers through speciﬁc hydrogen bonds and ionic
interactions. Although binding enthalpy provides a drug
candidate with afﬁnity and selectivity, enthalpic optimization
may take years and often only appear in second-generation
products61. In tolcapone, this property appears to be already
optimized for binding to both T4 pockets where multiple
interactions with different subunits of the protein occur.
In summary, we have shown that tolcapone, a FDA-approved
drug, is a potent inhibitor of TTR amyloidogenesis, prevents early
events of WT and mutant TTR-induced cytotoxicity, binds to and
stabilizes TTR in human plasma ex-vivo, to human V30M TTR in
transgenic mice plasma in vivo and importantly, to human
plasma TTR in vivo after oral administration at the therapeutic
doses used for Parkinson’s disease treatment.
At similar Tmax concentrations (B14mM) tolcapone’s TTR
stabilizing effect in vivo is almost two times larger than that of
tafamidis, in good agreement with all our in vitro data. In
contrast, diﬂunisal attains a high concentration in serum after
oral administration (4140mM)33, which compensates for its low
afﬁnity and negative binding cooperativity19 (Kd1¼ 75 nM;
Kd2¼ 1100 nM). In any case, the ratio between the maximum
concentration attained in plasma when the drug is administered
at therapeutic doses and the one needed to theoretically saturate
the two T4-binding sites in WT-TTR is 1.8- and 4.5-fold higher in
tolcapone than in diﬂunisal and tafamidis, respectively.
The efﬁcacy of a given drug depends on its target afﬁnity,
speciﬁcity and attainable serum concentrations, but also on its
clearance rate. A limitation of tolcapone in relation to both
diﬂunisal and tafamidis is its shorter half-life in plasma (B2–3 h);
however, preliminary data indicate that this limitation can be at
least partially overcome using slow release formulations.
Tolcapone has the potential of becoming an efﬁcacious small
molecule to prevent the onset of TTR deposition diseases;
tolcapone could be in the market in a relatively short time frame
as it has already entered into clinical trials (ClinicalTrials.gov
Identiﬁer: NCT02191826/EudraCT number: 2014-001586-27).
Importantly, the unique ability of tolcapone to penetrate the
blood–brain barrier40 and to reduce A25T-TTR aggregation
indicate that it could become the ﬁrst pharmacologic treatment
available for TTR leptomeningeal amyloidosis.
Methods
Recombinant TTR expression and puriﬁcation. WT, V30M, Y78F, A25T and
V122I-TTR variants were prepared as in refs 36,38.The recombinant TTR proteins
were produced using a pET expression system (Novagen). The mutant proteins
were prepared by PCR site-directed mutagenesis using the QuickChange kit
(Stratagene). Both WT and mutant proteins were expressed in Escherichia coli
BL21- (DE3) cells harbouring the corresponding plasmid. Expression cultures
in lysogeny broth (LB) medium containing 50 mgml 1 kanamycin were grown at
37 C to an optical density (at 600 nm) of 0.6, then induced by addition of
isopropyl-b-D-thiogalactoside (1mM ﬁnal concentration), grown at 37 C for 20 h,
and harvested by centrifugation (13,700g for 15min). After cell lysis by sonication,
intra-cellular proteins were fractionated by ammonium sulfate precipitation. The
TTR-containing fraction precipitated between 55 and 85% ammonium sulfate. The
precipitate was dissolved in 20mM Tris, pH 7.2, 0.1M NaCl and dialysed against
the same buffer. It was applied to a Q-Sepharose High Performance (Amersham
Biosciences) anion exchange column and eluted with a linear gradient 0.1–0.5M
NaCl in 20mM Tris, pH 7.2. TTR-enriched fractions were dialysed against 5mM
Tris, pH 7.2, 2.5mM NaCl, lyophilized and redisolved in a small volume of buffer
(10mM Tris, pH 7.2, 0.1mM NaCl). The protein was further puriﬁed by gel
ﬁltration chromatography on a Superdex 75 prep grade column (Amersham
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Biosciences) and eluted with 10mM Tris, pH 7.2, 0.1M NaCl. Purest fractions were
combined and dialysed against 20mM phosphate buffer, pH 7.6, 100mM KCl
and stored at 4 C. The purity of protein preparations was 495% as judged by
SDS–PAGE. Protein concentration was determined spectrophotometrically at
280 nm using an extinction coefﬁcient of 77,600M 1 cm 1.
TTR in vitro aggregation inhibition assays. The initial screening protocol used
for the 30 top ranked molecules from the docking experiment is described in detail
elsewhere36. Brieﬂy, Y78F-TTR solutions (7mM in 10mM sodium phosphate,
100mM KCl, 1mM EDTA, pH 7.6) were incubated with varying concentrations of
the test compounds (ranging from 0 to 40 mM) for 30min at 37 C. All compounds
stock solutions were prepared in dimethylsulphoxide (DMSO). DMSO
concentration was adjusted to 5% (v/v) in the ﬁnal reaction assay mixture. After
this incubation period, the pH of the solutions was lowered by dilution with
400mM sodium acetate, 100mM KCl, pH 4.2. TTR aggregation was followed by
turbidity at 340 nm for 1.5 h on a 96-well microplate reader. All assays were
performed at least in duplicate. Aggregation of TTR was considered maximum in
the absence of compounds (100% aggregation). The same assay was performed for
WT-TTR and the V122I-TTR variant except that turbidity at 340 nm was
measured after 72 h incubation at 37 C. For A25T-TTR, incubation was measured
after 22 h incubation at pH 5.0 and 37 C, as previously described8. Because
tolcapone exhibits dose-dependent absorbance at 340 nm (Supplementary Fig. 2),
each individual measurement was corrected with a buffer containing the same
concentration of compound but devoid of TTR.
Sedimentation assay. TTR aggregation can also be measured by sedimentation
using centrifugation. It has previously been demonstrated that the TTR can be
partitioned between precipitates and supernatant with a recovery rate of 490%
with respect to the total initial protein48. TTR aggregation induction was
performed as described above. The samples of WT, V122I-TTR and A25T-TTR
incubated in the presence of different concentrations of tolcapone were centrifuged
at 20,000g for 1 h. The supernatant was carefully removed, and 400ml of Guanidine
(8M) was added to each sample and subsequently incubated for 1 h to unfold the
aggregated TTR. The amount of resolubilized TTR was measured by absorbance at
280 nm. The percentage of TTR precipitated was calculated with respect to total
(soluble) TTR at time 0.
TTR stabilization by tolcapone in the presence of urea. WT-TTR (1 mM in
PBS) was incubated with or without 10 mM of tolcapone for 30min. Urea was
added to attain a range of ﬁnal concentrations (0–9M) and the samples were
incubated for 72 h at RT. Fluorescence intensity measurements were performed on
a Jasco FP-8200 Spectroﬂuorometer. Trp ﬂuorescence was obtained by exciting the
samples at 280 nm and emission was collected from 300 to 400 nm. The ﬂuores-
cence intensity ratio 355/335 nm was plotted against urea concentration as a sensor
of folded protein, which for TTR in urea is equivalent to tetramer integrity15.
In another setting, WT-TTR (1.8 mM in PBS) was incubated with several
concentrations of tolcapone (0.9–8 mM) in 6.5M urea for 72 h at RT. The fraction
of unfolded TTR was measured and calculated as above. The TTR ﬂuorescence
after incubation at RT for 72 h in 9M urea was considered to correspond to that of
the unfolded state. Incubation of WT-TTR for 48 h with Guanidine hydrochloride
(6.5M) resulted in the same extent of denaturation. As a control, we also excited 1
and 10mM of tolcapone (PBS) in the absence and presence of TTR and observed
that this compound has no ﬂuorescence and does not interfere with Trp excitation
or emission at the used wavelengths (Supplementary Fig. 2).
Isothermal titration calorimetry. ITC was used to study the interaction between
TTR and tolcapone or tafamidis using an Auto-iTC200 calorimeter (MicroCal).
TTR at 5 mM located in the calorimetric cell was titrated against the drugs at
100mM in the injection syringe in PBS buffer pH 7.0, 100mM KCl, 1mM EDTA,
2.5% DMSO, at 25 C. A stirring speed of 1,000 r.p.m. and 2 ml injections
were programmed, with consecutive injections separated by 150 s to allow the
calorimetric signal (thermal power) to return to baseline. Experimental data were
analysed with a general model for a protein with two ligand-binding sites43,44
implemented in Origin 7.0 (OriginLab).
Crystallography and structure determination. Co-crystals of WT-TTR/
tolcapone and of V122I-TTR/tolcapone were obtained at 18 C by sitting drop
vapour diffusion methods after mixing a tenfold molar excess of ligand with
protein to ensure saturation. The reservoir solution contained between 15 and 25%
PEG 400, 200mM calcium chloride, 100mM HEPES, pH 7.0. Single crystals
appeared after 3 days from equal volumes of protein solution (10mgml 1 in
50mM Tris-HCl (pH 8.0), 100mM KCl, 1mM EDTA) and reservoir solution.
Crystals were cryo-protected in reservoir buffer containing 10% glycerol and
ﬂash-frozen in liquid nitrogen before diffraction analysis. Diffraction data were
recorded from cryo-cooled crystals (100 K) at the ALBA synchrotron in Barcelona
(BL13-XALOC beamline). Data were integrated and merged using XDS and scaled,
reduced and further analysed using CCP4 (Supplementary Table 2). The structure
of TTR/tolcapone complex was determined from the X-ray data by molecular
replacement using a previous TTR structure (PDB code 3TCT) as a model using
the programme MolRep. The initial electron density maps showed the butterﬂy
electron density map corresponding to tolcapone in the TTR dimer–dimer
interface that was manually built using the programme COOT. Model reﬁnement
was performed with Refmac and Phenix. Ramachandran analysis shows 98.00% of
residues (196) are in preferred regions and only 2.00% of residues (4) are in allowed
regions for the WT-TTR/tolcapone structure. For the V122I-TTR/tolcapone
structure, 96.30% of residues (104) are in preferred regions and only 3.70% of
residues (4) are in allowed regions. Reﬁnement and data statistics are provided in
Supplementary Table 2. Structural representations were prepared with PyMOL.
Binding competition assays using radioactive T4. Displacement of T4 from TTR
in plasma (ex vivo) was assayed qualitatively by incubation of 5 ml of human plasma
with 0.25–0.5 ml of [125I]T4 (speciﬁc radioactivity 1,250 mCi mg 1; concentration
320 mCiml 1; Perkin Elmer) in the presence of 1mM of test compounds. The
negative control was performed by adding 1 ml of PBS. The samples were incubated
for 1 h at RT. The same incubations were performed using mouse plasma treated
in vivo with the small molecules or vehicle control (gavage administration). After
incubation, plasma proteins were separated by native PAGE as in ref. 42. The gels
were dried and subjected to phosphor imaging (Typhoon 8600; Molecular
Diagnostics, Amersham Biosciences) for quantiﬁcation, and the bands analysed
using the ImageQuant program version 5.1. The three observed bands correspond
to the three-major T4-binding plasma proteins: TBG, ALB and TTR, the later
presenting the most anodal migration.
Stability studies by native PAGE and isoelectric focusing (IEF). TTR tetramer
stabilization by compounds was assessed by IEF under semi-denaturing conditions
as described in detail in ref. 62. Brieﬂy, 30 ml of human plasma from WT and
V30M-TTR carriers (n¼ 6) were incubated overnight at 4 C with 5 ml of
compounds at 10mM (in DMSO). Plasma samples from transgenic mice
expressing V30M-TTR that had been treated with tolcapone or vehicle were
analysed in the same way (see below). The plasma samples were subjected to native
PAGE and the gel band containing TTR was excised and applied to an IEF gel. IEF
was carried out under semi-denaturing conditions (4M urea), containing 5% (v/v)
ampholytes, pH 4–6.5 (GE Healthcare), at 1,200V for 6 h. Proteins were stained
with Coomassie blue. The gels were scanned (HP Scanjet 4470c, Hewlett Packard)
and subjected to densitometry analysis using the ImageQuant program. The ratio
of TTR tetramer over total TTR (TTR tetramerþmonomer) was calculated for
each plasma sample and the % TTR tetramer stabilization was calculated as
100 ((ratio sample—ratio non-treated)/ratio non-treated). Where ‘ratio sample’
is tetramer/total TTR in the presence of compound; and ‘ratio non-treated’ is
tetramer/total TTR of non-treated plasma sample from the same donor. For the
mice plasma analysis, each gel contained at least one sample from control animals
serving as internal control, to correct for the gel to gel variability (seven gels were
run in total, each sample was analysed at least in two independent gels). The ratios
of TTR tetramer/Total TTR were calculated for each sample collected at the end of
the assay, from controls and drug-treated mice. The ratio of each sample was then
expressed as fold increase with respect to control samples from vehicle-treated
animals (ratio drug treated sample/average ratio vehicle samples from the
corresponding gel). The results are represented as average fold increase±standard
deviation.
Ex vivo stability studies by immunoturbidity. A pool of lithium-heparin plasma
samples from healthy volunteers stored at  80 C was thawed on ice. Partially
clotted particles were removed by spinning the samples for 2min at 10,000g.
Samples were then incubated with various concentrations of tolcapone (from a
DMSO stock stored at  20 C), for 15min at RT. Addition volume was limited to
maximum 1.5% (v/v) of sample. A control in which DMSO vehicle was added was
included in the experimental design. Samples were then mixed with a urea solution
(8M in 50mM potassium phosphate pH 7.0, 100mM NaCl, 1mM dithiothreitol,
1mM EDTA) to a ﬁnal urea concentration of 4.8M, and incubated for various time
points at controlled RT conditions. At the time of measuring, an aliquot was taken
and a 2.5M glutaraldehyde solution was added to a ﬁnal concentration of 40mM.
The samples were quickly vortexed and incubated for 4min at RT. Then, NaBH4
was added to a ﬁnal concentration of 48mM to quench the reaction. Samples were
transferred to a measuring tube and read by immunoturbidity after 5min at RT.
Immunoturbidity was measured in a Siemens Automate Dimension EXL200
instrument, using the Siemens Prealbumin (PALB) reagent and calibrator
according to the manufacturer’s instructions. The slight decrease observed in
samples crosslinked immediately after adding urea (time 0) possibly reﬂects
changes in antibody recognition not directly associated with TTR denaturation,
as they are not affected by the presence of compound. Experiments were performed
at least three times in duplicate.
Cell toxicity assays. The AC16 human cardiomyocyte cell line46 was maintained
in DMEM:F12 supplemented with 10% fetal bovine serum (FBS) 2mM
L-glutamine, 100Uml 1 penicillin, 100mgml 1 streptomycin at 37 C in a 5%
CO2 incubator as in refs 38,47. AC16 cells (70–90% conﬂuent) were seeded in black
wall clear bottom 96-well plates (250 cells per well) in Opti-MEM, supplemented
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with 5% FBS, 2mM L-glutamine, 100Uml 1 penicillin, 100 mgml 1
streptomycin, 1mM HEPES and 45mM CaCl2 (seeding Opti-MEM medium) and
incubated overnight at 37 C. The seeding Opti-MEM medium was removed and
immediately replaced with 100 ml per well of the appropriate TTR solutions or
vehicle (1:1) HBSS/Opti-MEM supplemented with glutamine and antibiotics and
0.4mgml 1 fatty acid- free BSA. AC16 cells were treated with TTR/compound
mixtures (1:2 molar equivalents, ﬁnal TTR concentration 8 mM), TTR alone
(8mM), drugs alone (16mM) or vehicle controls, for 24 h at 37 C. Cell viability was
then measured by resazurin reduction assay, a process by which metabolically
active cells reduce the substrate resazurin into the highly ﬂuorescent resoruﬁn47.
Cell viability was calculated as percentage of ﬂuorescence intensity (Exc/Em
530/590 nm) of the treated cells with respect to cells treated with vehicle only
(no TTR or compounds) after subtraction of the blanks (wells with no cells). The
assays were done at least in triplicate and repeated twice. The data shown represent
the average of two independent experiments, the bars represent the standard error
of the mean (s.e.m.).
Rat Schwannoma cells (RN22, American Type Cell Collection), 80% conﬂuent
cells in DMEM with 10% FBS, were exposed for 24 h to 2 mM of Y78F-TTR
oligomers as detailed in ref. 36. These oligomers were obtained by incubation of
soluble Y78F-TTR either in the absence or in the presence of 10M equivalent
excess (ﬁnal concentration 20 mM) of test compounds at 37 C for 6 days. The cells
were then trypsinized and cell lysates were prepared and used for determination of
caspase-3 activation with the CaspACE ﬂuorimetric 96-well plate assay system
(Sigma), following the manufacturer’s instructions. Protein concentration in the
cell lysates was determined with the Bio-Rad Bradford protein assay kit (Bio-Rad).
Caspase-3 activation values were normalized by protein concentration in each
experimental condition. The percentage of caspase-3 activation relative to the
maximal activation was calculated. The maximal caspase-3 activation was
considered to be that of cells treated with oligomers in the absence of inhibitors
(mediaþTTR oligo). The assays were done in duplicate and repeated twice.
The data shown represent the average of two independent experiments, the bars
represent the standard error of the mean (s.e.m.). The data were analysed by
Student’s t-test using Microsoft Excel to establish signiﬁcant changes.
Dot-blot ﬁlter assay for quantiﬁcation of TTR aggregation. The rat
Schwannoma cell line RN22 stably co-transfected with TTR L55P cDNA under the
control of the metallothionein promoter was used to test the inhibitors of TTR
aggregation as in ref. 51. Cells were grown in six-well cell culture plates to 50%
conﬂuence in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin
and G418 (1mgml 1, Calbiochem) at 37 C in a 95% humidiﬁed atmosphere and
5% CO2. To investigate the effect of test compounds on TTR aggregation, cells were
incubated with 1 mM of tolcapone and tafamidis in the medium for 48 h and then
for further 3 days with the compounds simultaneously with 100 mM ZnSO4
(to induce TTR expression), until reaching B80% cell conﬂuence. The cells were
then incubated with serum-free medium supplemented with ZnSO4 and test
compounds for additional 24 h. TTR in the medium was quantiﬁed by ELISA, and
the volume of medium corresponding to 500 ng of TTR was applied on to a 0.2-mm
pore cellulose acetate membrane ﬁlter (Schleicher and Schuell) using a manifold
system (Gibco BRL) to separate soluble proteins from aggregates. TTR was
immuno-detected using a rabbit anti-human TTR (DAKO, A0002; 1:500) followed
by a secondary antibody, anti-rabbit IgG-horseradish peroxidase conjugate
(1:1,500). Detection was performed with ECL (GE Healthcare). Dot blot
quantiﬁcation was performed using the ImageQuant program. The percentage
of aggregation inhibition was calculated as 100 ((Control—Treated)/Control).
Experiments were repeated three times in triplicate.
Tolcapone oral administration in mice. Animal experiments were approved by
the Portuguese General Veterinarian Board and animals were kept and used strictly
in accordance with the National rules and the European Community Council
Directive (86/609/EEC) for the care and handling of laboratory animals.
Transgenic mice expressing human V30M-TTR received oral doses of tolcapone
by gavage as follows: (I) 30mg kg 1, two doses spaced 8 h (six animals);
(II) 100mg kg 1, two doses spaced 8 h (six animals); (III) 300mg kg 1, two doses
spaced 8 h (six animals); (IV) 100mg kg 1, three doses in 3 h intervals (three
animals) and (V) 100mg kg 1, four doses in 3 h intervals (three animals).
Nine animals administered with vehicle (PBS with 0.04% Tween 80 and 0.2%
methylcellulose) were used as controls. Blood was collected from tail vein 16 h
before treatment with the ﬁrst dose (time, t¼ 0), to minimize the stress of the
animals before gavage. Collection of blood at the end of the experiment (t¼ end)
was done from the posterior vena cava upon killing the animals after anaesthesia
with ketamine/medetomide (75 and 1mg kg 1, respectively). The animals were
killed 1 h after the administration of last dose, which corresponds to 9 h for groups
I–III and vehicle; 7 h for group IV and 10 h for group V.
Tolcapone oral administration in humans. Two healthy volunteers of 49 years of
age were treated with tolcapone (TASMAR) with a single dose of 200 or two doses
of 200mg in a 30-min interval. Blood was collected 30min before administration
and 2 h after the dose in BD Vacutainer tubes with Lithium-Heparin and gel for
plasma separation, following the manufacturer’s instructions. Brieﬂy, after gently
mixing the tubes by inversion, blood was centrifuged at 1,300g for 10min at 20 C.
Supernatants were collected and immediately stored at  80 C until analysis.
TTR stabilization after oral administrations in humans. For TTR stabilization
analysis, frozen plasma samples were thawed on ice. Samples were then mixed with
a 8M urea solution (in 40mM sodium phosphate pH 7.4 and 80mM KCl) to a
ﬁnal urea concentration of 4.8M. One aliquot was taken immediately after adding
urea (time 0) and the rest were incubated for 48 h at controlled RT conditions.
After the incubation time points (0 or 48 h), TTR was crosslinked with 40mM
glutaraldehyde (2.5M stock solution). The samples were quickly vortexed and
incubated for 4min at RT. Then, NaBH4 was added to a ﬁnal concentration of
48mM to quench the reaction. Samples were transferred to a measuring tube and
read by immunoturbidity after 5min at RT. Immunoturbidity was measured
in a Beckman Coulter AU680 ISE instrument (Beckman Coulter), using the
Olympus OSR6175 reagent and calibrator ODR3029 (Olympus) according to the
manufacturer’s instructions. Analysis was performed in triplicates. Informed
consent was obtained from all subjects and the protocol was approved by the Ethics
Committee of Hospital Vall d’Hebron (Barcelona).
Tolcapone quantiﬁcation in human plasma. Frozen plasma samples were thawed
at RT and tolcapone levels were quantiﬁed by UPLC-MS/MS based on the methods
described in refs 63,64. Brieﬂy, tolcapone and its internal standard (tolcapone-D4)
were extracted from human plasma by methanol protein precipitation. Extracted
samples were analysed on a Waters Acquity UPLC coupled with a Waters Xevo TQ
MS triple quadrupole mass spectrometer. Chromatographic separation was
achieved on an Acquity HSS C18 column using a gradient elution with the mobile
phase of methanol and 0.1% formic acid in water. Analytes were monitored using
electrospray-negative ionization mass spectrometry in the MRM mode
(m/z¼ 271.844181 for tolcapone and 275.864184.86 for tolcapone-D4).
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